There is strong evidence indicating that CYP2B6 polymorphisms are involved in the development not only of solid tumors, such as breast cancer (Justenhoven et al., 2014) and hepatocellular carcinoma (Yan et al., 2017), but also in hematological malignancies (Alazhary, Shafik, Shafik, & Kamel, 2015; Berkoz & Yalin, 2009; Daraki et al., 2014; Yuan et al., 2011). This evidence concerns the gene CYP2B6 and breast carcinoma.